TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12789172
Drug: Azelaic acid
Normalized name: Azelaic Acid
DrugBank: Azelaic acid (DB00548)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Azelaic acid (15%) gel
Study: 2884152
Drug: Loratadine 40
Normalized name: Loratadine
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Loratadine 40 mg once daily
Study: 2266679
Drug: Aluminum hydroxide
Normalized name: Aluminum Hydroxide
DrugBank: Aluminum hydroxide (DB06723)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aluminum hydroxide gel (Al[OH]3) (5 ml) alone
Study: 2266679
Drug: Al[OH]3 (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Al[OH]3 (5 ml) plus calcium acetate (Ca acetate) (1330 mg)
Study: 2266679
Drug: Al[OH]3 (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Al[OH]3 (5 ml) plus calcium citrate (Ca citr) (950 mg)
Study: 24274323
Drug: High-fiber snacks
Normalized name: fiber
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-fiber snacks (10-12 g dietary fiber per day)
Study: 21262918
Drug: Fructo-oligosaccharides (FOS)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fructo-oligosaccharides (FOS) 15 g/day for 4 weeks
Study: 7816008
Drug: Intravenous calcitriol
Normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous calcitriol (IVC)
Study: 7816008
Drug: Oral calcitriol
Normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral calcitriol (ORC)
Study: 3281679
Drug: Acipimox (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acipimox (400 mg t.i.d. for type II patients, 250 mg t.i.d. for type IV patients)
Study: 3281679
Drug: Acipimox (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acipimox (400 mg t.i.d. for type II patients)
Study: 25413485
Drug: IV analgesia
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV analgesia (piritramide 7.5 mg IV, plus oral metamizole)
Study: 22111896
Drug: Eicosapentaenoic acid
Normalized name: eicosapentaenoic acid
DrugBank: Icosapent (DB00159)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eicosapentaenoic acid (EPA) and cyclo-oxygenase-2 (COX-2) inhibitor celecoxib with progressive resistance training (PRT) and essential amino acids high in leucine.
Study: 22111896
Drug: Eicosapentaenoic acid
Normalized name: eicosapentaenoic acid
DrugBank: Icosapent (DB00159)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eicosapentaenoic acid (EPA) and cyclo-oxygenase-2 (COX-2) inhibitor celecoxib.
Study: 16841563
Drug: Aripiprazole (10-15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aripiprazole (10-15 mg/day)
Study: 16841563
Drug: Haloperidol (9-15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (9-15 mg/day)
Study: 12581571
Drug: GI ‐‐>
Approvals — FDA: no, EMA: no, PMDA: no
Description: GI ‐‐> VC regimen (gemcitabine 1000 mg/m² + ifosfamide 1500 mg/m² followed by vinorelbine 25 mg/m² + cisplatin 100 mg/m²)
Study: 12581571
Drug: VC ‐‐>
Approvals — FDA: no, EMA: no, PMDA: no
Description: VC ‐‐> GI regimen (vinorelbine 25 mg/m² + cisplatin 100 mg/m² followed by gemcitabine 1000 mg/m² + ifosfamide 1500 mg/m²)
Study: 12581571
Drug: VC regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: VC regimen (vinorelbine 25 mg/m² + cisplatin 100 mg/m²)
Study: 12581571
Drug: GC regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: GC regimen (gemcitabine 1400 mg/m² + cisplatin 100 mg/m²)
Study: 11127169
Drug: Consultation behaviour
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Consultation behaviour for significant new onset symptoms (rectal bleeding, abdominal pain, change in bowel habit).
Study: 8737130
Drug: sparfloxacin 200
Normalized name: sparfloxacin 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: sparfloxacin 200 mg once daily for 5 days following a loading dose of 400 mg on day 1
Study: 8737130
Drug: cefuroxime axetil
Normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: cefuroxime axetil 250 mg twice daily for 8 days
Study: 1317697
Drug: preoperative etoposide‐platinum
Approvals — FDA: no, EMA: no, PMDA: no
Description: preoperative etoposide‐platinum (EP) chemotherapy‐surgery‐postoperative EP
Study: 29632222
Drug: Aspirin use
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin use (solo practices)
Study: 26443196
Drug: Clopidogrel napadisilate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel napadisilate 75 mg
Study: 23026843
Drug: Clopidogrel bisulfate
Normalized name: Clopidogrel Bisulfate
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Clopidogrel bisulfate 75 mg
Study: 24532997
Drug: Armodafinil 200
Normalized name: armodafinil 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Armodafinil 200 mg once daily
Study: 21874559
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg bilastine
Study: 23742030
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg bilastine
Study: 23742030
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg bilastine
Study: 20008947
Drug: Olanzapine long-acting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine long-acting injection (high dose, 300 mg every 2 weeks)
Study: 20008947
Drug: Olanzapine long-acting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine long-acting injection (medium dose, 405 mg every 4 weeks)
Study: 20008947
Drug: Olanzapine long-acting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine long-acting injection (low dose, 150 mg every 2 weeks)
Study: 20008947
Drug: Olanzapine long-acting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine long-acting injection (very low dose, 45 mg every 4 weeks)
Study: 20008947
Drug: Olanzapine long-acting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine long-acting injection (all doses combined)
Study: 20008947
Drug: Olanzapine long-acting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine long-acting injection (high dose)
Study: 20008947
Drug: Olanzapine long-acting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine long-acting injection (medium dose)
Study: 20008947
Drug: Olanzapine long-acting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine long-acting injection (low dose)
Study: 20008947
Drug: Olanzapine long-acting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine long-acting injection (very low dose)
Study: 20008947
Drug: Olanzapine long-acting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine long-acting injection and oral olanzapine
Study: 20008947
Drug: Olanzapine long-acting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine long-acting injection
Study: 20938374
Drug: Podophyllotoxin 0.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Podophyllotoxin 0.5% solution
Study: 12902571
Drug: Podophyllotoxin 0.15%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Podophyllotoxin 0.15% cream
Study: 12902571
Drug: Podophyllotoxin solution
Normalized name: podophyllotoxin
DrugBank: Podofilox (DB01179)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Podophyllotoxin solution
Study: 12902571
Drug: Podophyllotoxin cream
Normalized name: podophyllotoxin
DrugBank: Podofilox (DB01179)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Podophyllotoxin cream
Study: 2117741
Drug: Overnight, 12-hour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overnight, 12-hour nasogastric infusions plus daytime oral feedings (group 2)
Study: 2117741
Drug: Oral feedings
Normalized name: SET,FEEDING
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral feedings alone (group 3)
Study: 22577906
Drug: Morphine 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 7.5 mg
Study: 18571875
Drug: Integrated CD
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Integrated CD and primary care during the index treatment episode
Study: 16781291
Drug: Famciclovir single-dose
Normalized name: Famciclovir
DrugBank: Famciclovir (DB00426)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Famciclovir single-dose (1500 mg once)
Study: 16781291
Drug: Famciclovir single-day
Normalized name: Famciclovir
DrugBank: Famciclovir (DB00426)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Famciclovir single-day (750 mg twice a day for 1 day)
Study: 31299013
Drug: Nonstudy oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonstudy oral PrEP use
Study: 31299013
Drug: Oral PrEP
Normalized name: Iron bivalent, oral preparations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral PrEP users
Study: 31299013
Drug: Continuation of
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuation of oral PrEP after study completion
Study: 24825486
Drug: Sustained-release methylphenidate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release methylphenidate (MPH-SR)
Study: 12240793
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg/day for 4 weeks
Study: 10406816
Drug: Beta-blockade therapy
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blockade therapy
Study: 8884862
Drug: Duraflo II
Normalized name: Duraflor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duraflo II heparin-coated circuit
Study: 6339595
Drug: Dutimelan 8-15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dutimelan 8-15 regimen (DTM 8-15): 7 mg of prednisolone acetate and 4 mg of prednisolone alcohol at 8 A.M., 15 mg of cortisone acetate and 3 mg of prednisolone alcohol at 3 P.M., placebo at 8 P.M.
Study: 6339595
Drug: Placebo at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo at 8 A.M., 15 mg of cortisone acetate and 3 mg of prednisolone alcohol at 3 P.M., 7 mg of prednisolone acetate and 4 mg of prednisolone alcohol at 8 P.M. (Rx 15-20).
Study: 29862925
Drug: Psychodynamic online
Normalized name: FILTER,SUCTION,INLINE #FHBF200S
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychodynamic online treatment
Study: 24638270
Drug: Low dose-fractionation
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low dose-fractionation (LD) group, total doses of 55 Gy and 44 Gy in 22 fractions to PTV1 and PTV2, respectively.
Study: 24638270
Drug: High dose-fractionation
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose-fractionation (HD) group, total doses of 66 Gy and 55 Gy in 22 fractions to PTV1 and PTV2, respectively.
Study: 12107606
Drug: 100 microg
Normalized name: Digoxin 100 microgram oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 microg BDP as one inhalation from 100‐microg/actuation strength
Study: 8703667
Drug: HN-65021 (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: HN-65021 (5 mg)
Study: 8703667
Drug: HN-65021 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: HN-65021 (10 mg)
Study: 8703667
Drug: HN-65021 (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: HN-65021 (100 mg)
Study: 28528015
Drug: Exposure-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exposure-based cognitive behavior therapy (CBT)
Study: 30644767
Drug: Exposure-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exposure-based cognitive behavior therapy (CBT) and Psychoeducation plus relaxation training (PRT)
Study: 19583078
Drug: Remifentanil continuous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil continuous infusion of 0.4 microg x kg(‐1) x mn(‐1) (GR n = 15)
Study: 2693996
Drug: Oxiracetam (800-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxiracetam (800-mg tablets), given twice daily for 12 weeks
Study: 2693996
Drug: Placebo, given
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, given twice daily for 12 weeks
Study: 30659024
Drug: SoC EGFR-TKI
Normalized name: Egfr t790m inhibitor pf-06747775
DrugBank: Mavelertinib (DB16228)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SoC EGFR-TKI (gefitinib 250 mg or erlotinib 150 mg, orally, once daily)
Study: 28753958
Drug: MNP+Fe (12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: MNP+Fe (12.5 mg iron)
Study: 22344561
Drug: Intranasal insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal insulin (160 IU) administered postprandially after lunch
Study: 22344561
Drug: Intranasal insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal insulin (160 IU) administered in the fasted state
Study: 22344561
Drug: Placebo (vehicle)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (vehicle) administered postprandially after lunch
Study: 15212189
Drug: Intravenous 5-isosorbide
Normalized name: hydralazine
DrugBank: Hydralazine (DB01275)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous 5-isosorbide mononitrate (5-ISMN)
Study: 9743398
Drug: bupivacaine with
Approvals — FDA: no, EMA: no, PMDA: no
Description: bupivacaine with sufentanil 0.5 microg/ml
Study: 9743398
Drug: bupivacaine with
Approvals — FDA: no, EMA: no, PMDA: no
Description: bupivacaine with sufentanil 1 microg/ml
Study: 9743398
Drug: bupivacaine with
Approvals — FDA: no, EMA: no, PMDA: no
Description: bupivacaine with sufentanil 1.5 microg/ml
Study: 30965213
Drug: Prophylactic amoxicillin/clavulanic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic amoxicillin/clavulanic acid from day 29 after the start of treatment until 14 days after completion of chemoradiotherapy
Study: 30965213
Drug: Prophylactic amoxicillin/clavulanic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic amoxicillin/clavulanic acid
Study: 24916838
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) insulin (duration 48 h)
Study: 20970238
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of TGCS interventions
Study: 18425015
Drug: Preoperative radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative radiation therapy (for patients unable to walk at surgery)
Study: 8241527
Drug: Ranitidine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (300 mg nocte)
Study: 8241527
Drug: Ebrotidine (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ebrotidine (800 mg nocte)
Study: 8241527
Drug: Ranitidine and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine and Ebrotidine (both treatments)
Study: 3531860
Drug: Interferon alpha-2b
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon alpha-2b (1 X 10(6) IU) injected into warts three times weekly for three weeks
Study: 3531860
Drug: Placebo injected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo injected into warts three times weekly for three weeks
Study: 22471290
Drug: Aspirin 100
Normalized name: aspirin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 100 mg twice daily
Study: 22471290
Drug: Aspirin 200
Normalized name: aspirin 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 200 mg once daily
Study: 18339977
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine plus insulin lispro
Study: 18339977
Drug: NPH insulin
Normalized name: NPH Insulin, Human 300 UNT per 3 ML Prefilled Syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: NPH insulin plus unmodified human insulin
Study: 1555991
Drug: Preoperative hyperthermia
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative hyperthermia with radiation therapy (5000‐5040 cGy at 180‐200 cGy per fraction, hyperthermia delivered 30‐60 minutes after radiation for 60 minutes)
Study: 1555991
Drug: One hyperthermia
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One hyperthermia treatment per week for a total of five treatments
Study: 1555991
Drug: Two hyperthermia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two hyperthermia treatments per week for a total of ten treatments
Study: 4003284
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) nifedipine (0.1, 0.2 and 0.4 microgram/kg/min over 10 minutes each)
Study: 4003284
Drug: Chronic oral
Normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chronic oral nifedipine (60 mg/day) in combination with atenolol
Study: 4003284
Drug: Atenolol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (100 to 200 mg/day)
Study: 30921737
Drug: Enriched CO2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enriched CO2 (800 ± 40 μmol mol-1) under salt stress (80 mmol L-1 NaCl)
Study: 30921737
Drug: Ambient CO2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ambient CO2 (400 μmol mol-1) under salt stress (80 mmol L-1 NaCl)
Study: 30921737
Drug: Enriched CO2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enriched CO2 (800 ± 40 μmol mol-1) under no salt stress (0 mmol L-1 NaCl)
Study: 30921737
Drug: Ambient CO2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ambient CO2 (400 μmol mol-1) under no salt stress (0 mmol L-1 NaCl)
Study: 21074013
Drug: 400 mcg
Normalized name: Biotin 400 MCG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mcg buccal misoprostol
Study: 17982603
Drug: 6 g
Normalized name: FAPi-46 GA-68
DrugBank: FAPi-46 GA-68 (DB18827)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 g of table sugar (Kandisin)
Study: 15077099
Drug: Early administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early administration of reduced-dose reteplase and abciximab combination therapy
Study: 15077099
Drug: Abciximab alone
Normalized name: Abciximab
DrugBank: Abciximab (DB00054)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Abciximab alone administered just before PCI
Study: 15077099
Drug: Facilitated PCI
Normalized name: PCI-27483
DrugBank: PCI-27483 (DB13000)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Facilitated PCI treatments (reteplase/abciximab combination therapy or abciximab alone)
Study: 22608582
Drug: 0.1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg/kg ketamine
Study: 3202097
Drug: Oral glucose
Normalized name: glucose Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral glucose coadministration with calcium at 222 mmol
Study: 3202097
Drug: Oral glucose
Normalized name: glucose Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral glucose coadministration with calcium at 0 mmol (control)
Study: 3202097
Drug: Oral glucose
Normalized name: glucose Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral glucose coadministration with calcium at 56 mmol
Study: 3202097
Drug: Oral glucose
Normalized name: glucose Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral glucose coadministration with calcium at 444 mmol
Study: 28359280
Drug: Placebo solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo solution (saline)
Study: 24297189
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with pegylated interferon‐α2a (135 µg weekly) plus ribavirin (200 mg daily)
Study: 24297189
Drug: Pegylated interferon‐α2a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegylated interferon‐α2a (135 µg weekly) monotherapy
Study: 24297189
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with pegylated interferon‐α2a plus ribavirin
Study: 24297189
Drug: Pegylated interferon‐α2a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegylated interferon‐α2a monotherapy
Study: 21600688
Drug: recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: recombinant human luteinizing hormone (rhLH) 37.5 IU
Study: 21600688
Drug: recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: recombinant human luteinizing hormone (rhLH) 75 IU
Study: 21600688
Drug: recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: recombinant human follicle‐stimulating hormone (rhFSH) alone
Study: 16764872
Drug: Medical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical treatment of miscarriage with 200 mg of mifepristone and 0.8 mg of misoprostol 1‐3 days after the event
Study: 14754942
Drug: Pediatric CI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pediatric CI therapy
Study: 11751485
Drug: Doxorubicin 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin 80 mg/m(2) as i.v. bolus followed by paclitaxel 200 mg/m(2) as a 24-h infusion and then cyclophosphamide 3.0 g/m(2) as a 1-h infusion (arm A)
Study: 11751485
Drug: Concurrent paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Concurrent paclitaxel and cyclophosphamide at the same doses (arm B)
Study: 9403288
Drug: Voglibose 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voglibose 5 mg t.i.d.
Study: 10779290
Drug: Sodium cromoglycate
Normalized name: Sodium cromoglycate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium cromoglycate (SCG) 30 mg/day
Study: 19650947
Drug: Inhaled pharmacotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled pharmacotherapy
Study: 19650947
Drug: Guidelines for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guidelines for inhaled pharmacotherapy
Study: 10729391
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose acetylcholine
Study: 10729391
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose acetylcholine
Study: 10729391
Drug: Antibodies to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibodies to oxidized low-density lipoprotein
Study: 8888218
Drug: Bolus tracking
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus tracking with 120 mL of contrast material
Study: 8888218
Drug: Fixed scanning
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed scanning delay with 120 mL of contrast material
Study: 8888218
Drug: Bolus tracking
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus tracking with 100 mL of contrast material
Study: 8888218
Drug: Fixed scanning
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed scanning delay with 100 mL of contrast material